5-氯吡嗪酰胺的体外抗分枝杆菌活性
In vitro antimycobacterial activity of 5-chloropyrazinamide.
作者信息
Cynamon M H, Speirs R J, Welch J T
机构信息
Veterans Affairs Medical Center, Syracuse, New York 13210, USA.
出版信息
Antimicrob Agents Chemother. 1998 Feb;42(2):462-3. doi: 10.1128/AAC.42.2.462.
Abstract
5-Chloropyrazinamide and 5-chloropyrazinoic acid were evaluated for in vitro activity against Mycobacterium tuberculosis, Mycobacterium bovis, and several nontuberculous mycobacteria by a broth dilution method. 5-Chloropyrazinamide was more active than pyrazinamide against all organisms tested. It is likely that this agent has a different mechanism of action than pyrazinamide.
摘要
采用肉汤稀释法评估了5-氯吡嗪酰胺和5-氯吡嗪酸对结核分枝杆菌、牛分枝杆菌以及几种非结核分枝杆菌的体外活性。5-氯吡嗪酰胺对所有测试菌株的活性均高于吡嗪酰胺。该药物的作用机制可能与吡嗪酰胺不同。
相似文献
1
In vitro antimycobacterial activity of 5-chloropyrazinamide.5-氯吡嗪酰胺的体外抗分枝杆菌活性
Antimicrob Agents Chemother. 1998 Feb;42(2):462-3. doi: 10.1128/AAC.42.2.462.
2
Antimycobacterial activity of a series of pyrazinoic acid esters.一系列吡嗪酸酯的抗分枝杆菌活性
J Med Chem. 1992 Apr 3;35(7):1212-5. doi: 10.1021/jm00085a007.
3
Pyrazinamide susceptibility testing in all isolates of the Mycobacterium tuberculosis complex - a critical analysis.结核分枝杆菌复合群所有分离株的吡嗪酰胺药敏试验——一项批判性分析
Rev Port Pneumol. 2012 Jul-Aug;18(4):188-9. doi: 10.1016/j.rppneu.2011.12.002. Epub 2012 Jan 17.
4
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.吡嗪酰胺和 5-氯吡嗪酰胺耐药的互斥基因型揭示了一种潜在的耐药预防策略。
Antimicrob Agents Chemother. 2010 Dec;54(12):5323-8. doi: 10.1128/AAC.00529-10. Epub 2010 Sep 27.
5
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.5-氯代吡嗪酰胺在感染结核分枝杆菌或牛分枝杆菌的小鼠中的活性。
Indian J Med Res. 2012 Nov;136(5):808-14.
6
Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide.结核分枝杆菌对吡嗪酰胺耐药的微量肉汤药物敏感性检测方法的评价。
Clin Microbiol Infect. 2011 Dec;17(12):1792-7. doi: 10.1111/j.1469-0691.2011.03508.x. Epub 2011 May 20.
7
Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide.用于检测结核分枝杆菌复合群分离株对吡嗪酰胺药敏性的ESP系统和BACTEC系统的比较。
J Clin Microbiol. 2002 Jun;40(6):2238-9. doi: 10.1128/JCM.40.6.2238-2239.2002.
8
In vitro antimycobacterial activities of pyrazinamide analogs.吡嗪酰胺类似物的体外抗分枝杆菌活性。
Antimicrob Agents Chemother. 1995 Sep;39(9):2088-91. doi: 10.1128/AAC.39.9.2088.
9
Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.BacT/ALERT PZA试剂盒与BACTEC 460TB PZA用于检测结核分枝杆菌对吡嗪酰胺敏感性的比较评估。
J Antimicrob Chemother. 2007 Sep;60(3):655-7. doi: 10.1093/jac/dkm252. Epub 2007 Jul 5.
10
Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?对吡嗪酰胺的耐药性是否能准确表明牛分枝杆菌的存在？
J Clin Microbiol. 2005 Jul;43(7):3530-2. doi: 10.1128/JCM.43.7.3530-3532.2005.
引用本文的文献
1
Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.吡嗪酸类似物作为潜在抗分枝杆菌剂的构效关系。
Bioorg Med Chem. 2022 Nov 15;74:117046. doi: 10.1016/j.bmc.2022.117046. Epub 2022 Oct 7.
2
T405, a New Penem, Exhibits Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren.T405，一种新型 Penem，对 M. abscessus 具有疗效，并与β-内酰胺类药物亚胺培南和头孢地尼具有协同作用。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0053622. doi: 10.1128/aac.00536-22. Epub 2022 May 31.
3
Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates and in a Mouse Model of Pulmonary Infection.奥马环素对脓肿分枝杆菌临床分离株的效价及肺部感染小鼠模型的疗效。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. doi: 10.1128/AAC.01704-21. Epub 2021 Oct 18.
4
β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.β-内酰胺类药物联合用药对脓肿分枝杆菌临床分离株表现出协同作用。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02545-20.
5
5-Alkylamino--phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation.5-（烷氨基）-苯并吡嗪-2-甲酰胺：设计、制备与抗分枝杆菌活性评价。
Molecules. 2020 Mar 28;25(7):1561. doi: 10.3390/molecules25071561.
6
-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents-The Synthesis and Biological Evaluation of Enantiomers.-吡嗪甲酰基取代的氨基酸作为潜在的抗分枝杆菌药物-对映异构体的合成与生物学评价。
Molecules. 2020 Mar 27;25(7):1518. doi: 10.3390/molecules25071518.
7
Phylogenetic and Biochemical Analyses of Mycobacterial l,d-Transpeptidases Reveal a Distinct Enzyme Class That Is Preferentially Acylated by Meropenem.分枝杆菌l,d-转肽酶的系统发育和生化分析揭示了一类独特的酶，该酶优先被美罗培南酰化。
ACS Infect Dis. 2019 Dec 13;5(12):2047-2054. doi: 10.1021/acsinfecdis.9b00234. Epub 2019 Oct 14.
8
Select β-Lactam Combinations Exhibit Synergy against .选择β-内酰胺类抗生素联合用药具有协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
9
Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA.吡嗪酰胺的抗结核活性不依赖于反翻译和 RpsA。
Sci Rep. 2017 Jul 21;7(1):6135. doi: 10.1038/s41598-017-06415-5.
10
The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography.通过正电子发射断层扫描测定5-[¹⁸F]氟吡嗪酰胺在结核分枝杆菌感染小鼠体内的生物分布。
PLoS One. 2017 Feb 2;12(2):e0170871. doi: 10.1371/journal.pone.0170871. eCollection 2017.
本文引用的文献
1
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.耐吡嗪酰胺结核分枝杆菌中pncA基因突变的特征分析
Antimicrob Agents Chemother. 1997 Mar;41(3):540-3. doi: 10.1128/AAC.41.3.540.
2
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.编码吡嗪酰胺酶/烟酰胺酶的基因pncA发生突变，会导致结核杆菌对抗结核药物吡嗪酰胺产生耐药性。
Nat Med. 1996 Jun;2(6):662-7. doi: 10.1038/nm0696-662.
3
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.成人及儿童结核病与结核感染的治疗。美国胸科学会及疾病控制与预防中心。
Am J Respir Crit Care Med. 1994 May;149(5):1359-74. doi: 10.1164/ajrccm.149.5.8173779.
4
Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.正丙基吡嗪酸酯对耐吡嗪酰胺结核分枝杆菌的活性：吡嗪酰胺作用机制及耐药机制的研究
Antimicrob Agents Chemother. 1995 Jun;39(6):1269-71. doi: 10.1128/AAC.39.6.1269.
5
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.具有广谱体外抗分枝杆菌活性的吡嗪酸酯。
J Med Chem. 1995 Sep 29;38(20):3902-7. doi: 10.1021/jm00020a003.
6
Pyrazinamide susceptibility and amidase activity of tubercle bacilli.结核杆菌的吡嗪酰胺敏感性及酰胺酶活性
Am Rev Respir Dis. 1967 Mar;95(3):461-9. doi: 10.1164/arrd.1967.95.3.461.
7
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Am Rev Respir Dis. 1989 Nov;140(5):1189-93. doi: 10.1164/ajrccm/140.5.1189.
8
Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?吡嗪酸作为吡嗪酰胺的活性部分，对结核分枝杆菌是否具有特异性活性？
Antimicrob Agents Chemother. 1989 Aug;33(8):1252-4. doi: 10.1128/AAC.33.8.1252.
9
Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis.结核病化疗和化学预防中的现有及新药方案。
Bull Int Union Tuberc Lung Dis. 1990 Jun-Sep;65(2-3):86-91.
10
Antimycobacterial activity of a series of pyrazinoic acid esters.一系列吡嗪酸酯的抗分枝杆菌活性
J Med Chem. 1992 Apr 3;35(7):1212-5. doi: 10.1021/jm00085a007.
Zotero 插件